Alnylam Pharmaceuticals (ALNY) Change in Cash (2017 - 2026)
Alnylam Pharmaceuticals (ALNY) has disclosed Change in Cash for 18 consecutive years, with $53.6 million as the latest value for Q1 2026.
- For Q1 2026, Change in Cash changed 0.03% year-over-year to $53.6 million; the TTM value through Mar 2026 reached $690.2 million, up 104.48%, while the annual FY2025 figure was $690.2 million, 348.83% up from the prior year.
- Change in Cash hit $53.6 million in Q1 2026 for Alnylam Pharmaceuticals, down from $166.0 million in the prior quarter.
- Across five years, Change in Cash topped out at $497.7 million in Q3 2022 and bottomed at -$285.9 million in Q1 2022.
- Average Change in Cash over 5 years is $52.4 million, with a median of $53.6 million recorded in 2025.
- Year-over-year, Change in Cash plummeted 144.27% in 2022 and then skyrocketed 2084.58% in 2024.
- Alnylam Pharmaceuticals' Change in Cash stood at -$206.8 million in 2022, then decreased by 6.52% to -$220.3 million in 2023, then skyrocketed by 39.25% to -$133.8 million in 2024, then surged by 224.03% to $166.0 million in 2025, then crashed by 67.7% to $53.6 million in 2026.
- According to Business Quant data, Change in Cash over the past three periods came in at $53.6 million, $166.0 million, and $376.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.